Escherichia coli Infections clinical trials
The registry lists 100 studies for Escherichia coli Infections across more than 10 countries. 22 are recruiting or about to start. 45 of them are mainly about Escherichia coli Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
Get an email when these change. Save the Escherichia coli Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Assistance Publique - Hôpitaux de Paris (5) · NIZO Food Research (5) · University of Pittsburgh (4) · Erasmus Medical Center (3) · U.S. Army Medical Research and Development Command (3) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · University Hospital, Basel, Switzerland (2)
What is being tested here
Drugs under test in Escherichia coli Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
7studies finish main data collection within a year
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7
- Dec 2026Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections · University of California, San Diego
- May 2027A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age · GlaxoSmithKline
- May 2027Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial · Johns Hopkins University
- Jun 2027A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) · Locus Biosciences
- Aug 2027Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection · University of Calgary
- Sep 2027Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria · Barbara Trautner
- Oct 2027Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant · SNIPR Biome Aps.
Who these studies take
Of the 13 Escherichia coli Infections studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger. 2 (15%) take children under 18. 1 (8%) are for women only and 0 (0%) for men only; 5 (38%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (15%) | 2 (15%) |
| 18 | 13 (100%) | 12 (92%) |
| 30 | 12 (92%) | 11 (85%) |
| 40 | 12 (92%) | 11 (85%) |
| 50 | 12 (92%) | 11 (85%) |
| 65 | 10 (77%) | 9 (69%) |
| 75 | 9 (69%) | 8 (62%) |
| 85 | 8 (62%) | 8 (62%) |
Across all 100 studies, recruiting or not: 41% stop at 75 or younger and 36% at 65; 26% take children; 10% are for women only and 9% for men only; 40% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
- Cefotetan Therapy for Escherichia Coli InfectionsOct 16, 2026NCT07318584
Newly registered4
- Randomized, Multicenter, Non-inferiority Trial Comparing the Efficacy of Fosfomycin Versus Fluoroquinolones or Cotrimoxazole as Oral Follow-up Treatment in Febrile Urinary Tract Infections in Men Caused by Susceptible EnterobacteriaNov 12, 2026NCT07932158
- Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority TrialNov 10, 2026NCT07928063
- Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)Oct 29, 2026NCT07905638
- Oral Fosfomycin as Sequential Oral Treatment for Multidrug-Resistant Escherichia Coli in Acute Bacterial ProstatitisOct 28, 2026NCT07902427
Studies
Recruiting first, then most recently updated. Showing 50 of 100. Browse all 100 → or search them.
- Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern FranceNot yet recruitingNCT076765131 country
- Randomized, Multicenter, Non-inferiority Trial Comparing the Efficacy of Fosfomycin Versus Fluoroquinolones or Cotrimoxazole as Oral Follow-up Treatment in Febrile Urinary Tract Infections in Men Caused by Susceptible EnterobacteriaNot yet recruitingNCT07932158Phase 3
- Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority TrialNot yet recruitingNCT07928063Phase 3
- Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)Not yet recruitingNCT07905638
- Cefotetan Therapy for Escherichia Coli InfectionsRecruitingNCT07318584Phase 21 country
- Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-TransplantRecruitingNCT06938867Phase 1/21 country
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)RecruitingNCT05488340Phase 21 country
- Hyperhydration in Children With Shiga Toxin-Producing E. Coli InfectionRecruitingNCT05219110Not applicable2 countries
- Bacteriophage Therapy in Spinal Cord Injury Patients With BacteriuriaRecruitingNCT06559618Phase 11 country
- A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of AgeRecruitingNCT06702449Phase 1/22 countries
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialRecruitingNCT06080698Not applicable1 country
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of CareRecruitingNCT07236944Phase 42 countries
- Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung InfectionsNot yet recruitingNCT07280598Phase 1
- Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of TreatmentRecruitingNCT04846803Not applicable1 country
- Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia ColiNot yet recruitingNCT07106944
- NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant BacteriaRecruitingNCT050177661 country
- An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"Not yet recruitingNCT06815549Phase 3
- Study of E. Coli Isolates From Recurrent Urinary Tract InfectionsRecruitingNCT058260671 country
- Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)RecruitingNCT06314880Phase 11 country
- Impact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in IndonesiaNot yet recruitingNCT059600841 country
- Clinical Outcomes in Patients With Infection by Resistant MicroorganismEnrolling by invitationNCT058800691 country
- Study of the Ecological and Evolutionary Dynamics of Escherichia Coli in the Digestive Commensal FloraRecruitingNCT051538241 country
- Oral Fosfomycin as Sequential Oral Treatment for Multidrug-Resistant Escherichia Coli in Acute Bacterial ProstatitisCompletedNCT07902427Phase 41 country
- Psychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal SurgeryCompletedNCT02970513Not applicable1 country
- Perinatal Transmission of MDR BacteriaCompletedNCT061484801 country
- Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia ColiCompletedNCT047645001 country
- Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus BacteriaTerminatedNCT038695931 country
- Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract InfectionsCompletedNCT05138822Phase 11 country
- Meatsafe Food Storage and Diarrhea Prevention Trial in Urban BangladeshCompletedNCT07332078Not applicable1 country
- A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic AreaTerminatedNCT03548064Phase 12 countries
- Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract InfectionWithdrawnNCT06482151
- Health Impacts of Street Vended FruitsCompletedNCT06858046Not applicable1 country
- Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing EnterobacteriaceaeSuspendedNCT03891433Phase 41 country
- Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing BacteremiaTerminatedNCT056133223 countries
- Egg Intervention During Pregnancy in IndonesiaActive, not recruitingNCT04694235Not applicable1 country
- Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University HospitalsCompletedNCT062524281 country
- Immunomodulation Therapy for Urinary Tract InfectionsCompletedNCT04049994Phase 41 country
- The Research of Novel Electrolyzed Water Spray to Eradicate Bacteria E-coli and an Attenuated Human Flu VirusCompletedNCT05797103Not applicable1 country
- Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation PatientsStatus unknownNCT02729116Phase 2/31 country
- Quinolone Resistance Profiles and Mechanisms of Staphylococcus Aureus and Escherichia Coli From Humans, Chicken and Catfish Farms in IndonesiaStatus unknownNCT05652556
- Preventing Urinary Tract Infections With E. Coli Nissle:Status unknownNCT04608851Phase 41 country
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 41 country
- Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)CompletedNCT040876818 countries
- Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)CompletedNCT041171138 countries
- The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421CompletedNCT028470651 country
- Cefuroxime Resistance in PyelonephritisCompletedNCT046163521 country
- Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult SubjectsCompletedNCT00654108Phase 11 country
- Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia ColiCompletedNCT045745961 country
- Safety Study of Chimeric Vaccine to Prevent ETEC DiarrheaCompletedNCT01644565Phase 11 country
- Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)CompletedNCT03404674Phase 11 country